FDA-cleared profile

iCAS-LV

HighRAD Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Support trained physicians in visualizing and evaluating physician-identified liver lesions on multi-phase reconstructed CT, including lesion size, shape, position, and change over time; not for standalone diagnosis or patient-management decisions.

Clinical role
Post-acquisition liver-lesion review and longitudinal analysis; the radiologist designates lesions, validates computed segmentations, and can manually correct them before semi-automatic matching and quantification.
Images and patients
CT/CTA · Liver (physician-identified liver lesions)
Key limitation
Keep in mind: The physician must identify lesions and validate or manually correct computed segmentations and matching. Results must not be used in isolation for diagnosis or patient management. The reviewed FDA performance data are based on a retrospective liver-lesion dataset and a dedicated phantom study; local scanner, protocol, interface, and clinical-population compatibility require confirmation.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Support trained physicians in visualizing and evaluating physician-identified liver lesions on multi-phase reconstructed CT, including lesion size, shape, position, and change over time; not for standalone diagnosis or patient-management decisions.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Liver (physician-identified liver lesions) Input: Multi-phase volume datasets of reconstructed contrast-enhanced CT scans in DICOM format received from PACS, with physician-identified liver lesions; compatible CT vendors and models are subject to the device labeling's DICOM requirements.
  • Who uses it?Intended users: Trained physicians, including radiologists and other physicians managing the patient.
  • What does the software produce?Output: Quantitative liver-lesion volumes and locations in prior and current scans, lesion diameter and volume, total lesion burden, volume and diameter change over time, existing/new/disappeared lesion labels, RECIST measurements, key slices, and DICOM-transferred processing results.
  • What is its most important limitation?Key limitation: The physician must identify lesions and validate or manually correct computed segmentations and matching. Results must not be used in isolation for diagnosis or patient management. The reviewed FDA performance data are based on a retrospective liver-lesion dataset and a dedicated phantom study; local scanner, protocol, interface, and clinical-population compatibility require confirmation.

Clinical takeaway. Clinical role: Support trained physicians in visualizing and evaluating physician-identified liver lesions on multi-phase reconstructed CT, including lesion size, shape, position, and change over time; not for standalone diagnosis or patient-management decisions.

Evidence takeaway. Evidence from the reviewed source record: FDA K231690 reports phantom testing on four scanner platforms and a retrospective standalone analysis of 108 patients from Israel, Italy, and the US, comprising 219 contrast-enhanced CT scans and 2,127 liver lesions. Three radiologists established the lesion ground truth. The reported performance evidence uses DICE, ASSD, SHD, volume, and RECIST measurements and includes volume and longitudinal-change agreement, not a diagnostic-detection endpoint.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Support trained physicians in visualizing and evaluating physician-identified liver lesions on multi-phase reconstructed CT, including lesion size, shape, position, and change over time; not for standalone diagnosis or patient-management decisions.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Post-acquisition liver-lesion review and longitudinal analysis; the radiologist designates lesions, validates computed segmentations, and can manually correct them before semi-automatic matching and quantification.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Multi-phase volume datasets of reconstructed contrast-enhanced CT scans in DICOM format received from PACS, with physician-identified liver lesions; compatible CT vendors and models are subject to the device labeling's DICOM requirements.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Quantitative liver-lesion volumes and locations in prior and current scans, lesion diameter and volume, total lesion burden, volume and diameter change over time, existing/new/disappeared lesion labels, RECIST measurements, key slices, and DICOM-transferred processing results.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Clinical radiology and PACS workflow; the FDA packet does not specify a facility type.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Trained physicians, including radiologists and other physicians managing the patient.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
The physician must identify lesions and validate or manually correct computed segmentations and matching. Results must not be used in isolation for diagnosis or patient management. The reviewed FDA performance data are based on a retrospective liver-lesion dataset and a dedicated phantom study; local scanner, protocol, interface, and clinical-population compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA K231690 reports phantom testing on four scanner platforms and a retrospective standalone analysis of 108 patients from Israel, Italy, and the US, comprising 219 contrast-enhanced CT scans and 2,127 liver lesions. Three radiologists established the lesion ground truth. The reported performance evidence uses DICE, ASSD, SHD, volume, and RECIST measurements and includes volume and longitudinal-change agreement, not a diagnostic-detection endpoint.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA K231690 reports phantom testing on four scanner platforms and a retrospective standalone analysis of 108 patients from Israel, Italy, and the US, comprising 219 contrast-enhanced CT scans and 2,127 liver lesions. Three radiologists established the lesion ground truth. The reported performance evidence uses DICE, ASSD, SHD, volume, and RECIST measurements and includes volume and longitudinal-change agreement, not a diagnostic-detection endpoint.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

iCAS-LV regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K231690
  • Samplen=108
  • IndependenceIndependence not established

K231690

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231690. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Multi-phase volume datasets of reconstructed contrast-enhanced CT scans in DICOM format received from PACS, with physician-identified liver lesions; compatible CT vendors and models are subject to the device labeling's DICOM requirements.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K231690: iCAS-LV

  2. Routing

    Source context, not route validation: Multi-phase studies are received from PACS and processing output is transferred back to PACS in DICOM; the device is described as PC-based and self-contained. Exact PACS interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K231690: iCAS-LV

  3. AI processing

    Source context, not route validation: The exact FDA package describes iCAS-LV as a PC-based, self-contained, noninvasive image analysis software application. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "It is a PC-based, self-contained, noninvasive image analysis software application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K231690: iCAS-LV

  4. Returned objects

    Source context, not route validation: Quantitative liver-lesion volumes and locations in prior and current scans, lesion diameter and volume, total lesion burden, volume and diameter change over time, existing/new/disappeared lesion labels, RECIST measurements, key slices, and DICOM-transferred processing results.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K231690: iCAS-LV

  5. Viewer/worklist/report

    Unresolved route: Quantitative liver-lesion volumes and locations in prior and current scans, lesion diameter and volume, total lesion burden, volume and diameter change over time, existing/new/disappeared lesion labels, RECIST measurements, key slices, and DICOM-transferred processing results.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K231690: iCAS-LV

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes iCAS-LV as a PC-based, self-contained, noninvasive image analysis software application. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "It is a PC-based, self-contained, noninvasive image analysis software application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
Multi-phase studies are received from PACS and processing output is transferred back to PACS in DICOM; the device is described as PC-based and self-contained. Exact PACS interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-08

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for iCAS-LV; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K231690
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Liver (physician-identified liver lesions)
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-03-01
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K231690 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K231690: iCAS-LV

    U.S. Food and Drug Administration - Published 2024-03-01 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. iCAS-LV model card (K231690)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K231690

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K231690 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252992

CT Rembra RT; CT Areta RT; CT Rembra

Philips Healthcare (Suzhou) Co., Ltd.

Authorized purpose: CT Rembra RT, CT Areta RT, and CT Rembra support whole-body diagnostic imaging, oncology, radiotherapy planning, interventional, vascular, neurological, cardiovascular, and qualified lung-screening workflows for all ages.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-23
FDA-cleared K252970

BriefCase-Triage: CARE Multi-triage CT Body

Aidoc Medical, Ltd.

Authorized purpose: Adult contrast-enhanced and non-contrast CT triage for 11 chest, abdominal, and pelvic findings: diverticulitis, abdominal-pelvic abscess, appendicitis, intestinal ischemia/pneumatosis, obstructive renal stone, small- and large-bowel obstruction, spleen injury, liver injury, kidney injury, and pelvic fracture.

Modality
CT/CTA
Anatomy
Chest, Abdomen, and Pelvis
Decision
2026-01-07
FDA-cleared K252029

AI-CVD

HeartLung Corporation

Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.

Modality
CT/CTA
Anatomy
Chest, abdomen, heart, lungs, liver, aorta, pulmonary artery, bone, muscle, and fat
Decision
2025-12-19
FDA-cleared K242624

Medical Image Post-processing Software (uOmnispace.CT)

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: uOmnispace.CT provides healthcare institutions with tools to view, manipulate, evaluate, and analyze medical CT images, including colon, lung, vessel, brain, cardiac, liver, rib, spine, dual-energy, perfusion, and cardiovascular applications described in the exact FDA submission.

Modality
CT/CTA
Anatomy
Colon, lungs and airway, vessels, brain, heart, liver, ribs, spine, and other CT regions
Decision
2025-05-14

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history